Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Patrys Limited ( (AU:PAB) ).
Patrys Limited has announced that its subsidiary, Nucleus Therapeutics Pty Ltd, received a rebate of $807,000 for the 2024/2025 financial year under the Federal Government’s R&D Tax Incentive scheme. This rebate supports the company’s ongoing innovation and growth efforts, potentially strengthening its position in the therapeutic antibody development industry.
More about Patrys Limited
Based in Melbourne, Australia, Patrys Limited is a therapeutic antibody development company focused on its deoxymab platform of cell-penetrating antibodies for various therapeutic indications.
Average Trading Volume: 1,573,885
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.63M
For a thorough assessment of PAB stock, go to TipRanks’ Stock Analysis page.